Literature DB >> 10088993

The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder.

M Dubois-Dalcq1, V Feigenbaum, P Aubourg.   

Abstract

Adrenoleukodystrophy (ALD) is caused by mutations in an ATP-binding-cassette transporter located in the peroxisomal membrane, which result in a fatal demyelinating disease in boys and a milder phenotype in men and some heterozygous women. There is no molecular signature to indicate a particular clinical course. The underlying molecular mechanisms of this disease have yet to be targeted clinically. Is the increase in very-long-chain fatty acids (VLCFA) the disease trigger? Why is there no phenotype in ALD null mice that show this increase? Do VLCFA destabilize human myelin, once formed, and lead to the inflammation seen in this genetic disease? Bone-marrow transplantation might save a child by providing normal brain macrophages and allowing myelin regeneration early in disease. The processes that underlie ALD challenge neuroscientists to elucidate peroxisomal transporter functions in the nervous system and to pursue the gene-transfer strategies leading to remyelination until a preventive therapy emerges.

Entities:  

Mesh:

Year:  1999        PMID: 10088993     DOI: 10.1016/s0166-2236(98)01319-8

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  28 in total

1.  ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.

Authors:  Mauhamad Baarine; Craig Beeson; Avtar Singh; Inderjit Singh
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

Review 2.  On the front of X-linked adrenoleukodystrophy.

Authors:  P Aubourg
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

Review 3.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

4.  Adrenal steroids in adrenomyeloneuropathy. Dehydroepiandrosterone sulfate, androstenedione and 17alpha-hydroxyprogesterone.

Authors:  Maria Wichers-Rother; Andreas Grigull; Piotr Sokolowski; Birgit Stoffel-Wagner; Wolfgang Köhler
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

Review 5.  MicroRNAs in oligodendrocyte and Schwann cell differentiation.

Authors:  Jason C Dugas; Lucia Notterpek
Journal:  Dev Neurosci       Date:  2011-02-23       Impact factor: 2.984

6.  A Novel Double Mutation in the ABCD1 Gene in a Patient with X-linked Adrenoleukodystrophy: Analysis of the Stability and Function of the Mutant ABCD1 Protein.

Authors:  Masashi Morita; Junpei Kobayashi; Kozue Yamazaki; Kosuke Kawaguchi; Ayako Honda; Kenji Sugai; Nobuyuki Shimozawa; Reiji Koide; Tsuneo Imanaka
Journal:  JIMD Rep       Date:  2013-02-12

7.  Atp-binding cassette transporter ABC2/ABCA2 in the rat brain: a novel mammalian lysosome-associated membrane protein and a specific marker for oligodendrocytes but not for myelin sheaths.

Authors:  C Zhou; L Zhao; N Inagaki; J Guan; S Nakajo; T Hirabayashi; S Kikuyama; S Shioda
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

Review 8.  Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis.

Authors:  Inderjit Singh; Aurora Pujol
Journal:  Brain Pathol       Date:  2010-07       Impact factor: 6.508

Review 9.  Auxin: regulation, action, and interaction.

Authors:  Andrew W Woodward; Bonnie Bartel
Journal:  Ann Bot       Date:  2005-03-04       Impact factor: 4.357

10.  Erucic acid is differentially taken up and metabolized in rat liver and heart.

Authors:  Cameron C Murphy; Eric J Murphy; Mikhail Y Golovko
Journal:  Lipids       Date:  2008-03-19       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.